Lanean...
Concomitant (177)Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
BACKGROUND: The role of concomitant peptide receptor radionuclide therapy (PRRT) and capecitabine therapy has shown benefit in gastroenteropancreatic neuroendocrine tumors. However, data reporting its role in paraganglioma (PGL) patients is lacking. The aim of this study was to evaluate the role of...
Gorde:
| Argitaratua izan da: | EJNMMI Res |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Springer Berlin Heidelberg
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6365580/ https://ncbi.nlm.nih.gov/pubmed/30725219 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13550-019-0484-y |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|